Ruxotemitide (LTX 315) 三氟乙酸盐
规格
| Cas Number | 1345407-05-7(free) |
| 规格或纯度 | ≥95% |
| 纯度 | ≥95% |
| 包装 | 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | Solubility (25°C) In vitro Water: 100 mg/mL (69.45 mM); |
| 序列 | Lys-Lys-Trp-Trp-Lys-Lys-Trp-Dip-Lys-NH2 |
| 简短描述 | Bcl-2 调节剂 |
| 英文简短描述 | Bcl-2 Modulators |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | Ruxotemitide（LTX 315，Oncopore 公司）是一种溶瘤肽，可通过 Bax/Bak 调节的线粒体膜通透作用杀死癌细胞。 |
| 描述 |
序列：Lys-Lys-Trp-Trp-Lys-Lys-Trp-Dip-Lys-NH2 |
| 英文描述 |
Information Ruxotemitide (LTX 315) Ruxotemitide (LTX 315, Oncopore) is the oncolytic peptide that kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. In vitro LTX-315 is highly active against both murine and human melanoma cell lines in vitro. while displaying low EC50 cytotoxic activity against human red blood cells.LTX-315 has been shown to induce the release of ATP and HMGB1 both being DAMPs involved in ICD. In vivo when syngeneic B16 melanomas are treated intralesionally, a majority of the animals (~80%) treated with LTX-315 experience a complete and long-lasting tumor regression. LTX-315 injection induces an extensive hemorrhagic necrosis of the tumor parenchyma and a massive infiltration of CD3+ T cells, indicating that the peptide induces a type of cell death that leads to an increase in the number of tumor-infiltrating lymphocytes (TILs). treatment of a single tumor with LTX-315 generates a systemic anti-tumor immune response that eradicated distant lesions and prevented reoccurrence following tumor rechallenge. |